

Literatur

- Abot A et al. (2014) The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor modulation, uncoupling nuclear and membrane activation. *EMBO Mol Med* 6:1328–46
- Apter D et al. (2016) Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). *Contraception* 94:366–73
- Apter D et al. (2017) Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. *Eur J Contracept Reprod Health Care* 22:260–7
- Bundeszentrale für gesundheitliche Aufklärung (Hrsg.) (2018) Verhütungsverhalten Erwachsener. BZgA, Köln, 2018. <https://www.forschung.sexualaufklaerung.de/verhuetung/verhuetungsverhalten-2018> (Stand: 17.12.2021)
- Chen MJ et al. (2022) Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. *Contraception* 116:44–50
- Coelingh Bennink HJT et al. (2008a) Estetrol review: Profile and potential clinical applications. *Climacteric* 11:47–58
- Coelingh Bennink HJT et al. (2008b) Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model. *Climacteric* 11:2–14
- Creinin MD et al. (2021) Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. *Contraception* 104:222–8
- Creinin MD et al. (2023) Combined oral contraceptive adherence and pregnancy rates. *Obstet Gynecol* 141(5):989–94
- Douxflis J et al. (2020) Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. *Contraception* 102(6):396–402
- Douxflis J et al. (2023a) Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation. *Thromb Res* 232:148–150
- Douxflis J et al. (2023b) Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. *Climacteric* 26(1):55–63
- Duijkers IJM et al. (2015a) A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. *Eur J Contracept Reprod Health Care* 20:419–27
- Duijkers IJ et al. (2015b) Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. *Eur J Contracept Reprod Health Care* 20:476–89
- Duijkers I et al. (2021) Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. *Contraception* 103(6):386–93
- Foidart JM et al. (2019) Unique vascular benefits of estetrol, a Native Fetal Estrogen with Specific Actions in Tissues (NEST). In: *Sex Steroids' Effects on Brain, Heart and Vessels*. Springer: Cham, Switzerland, 2019; pp. 169–195
- Foidart JM et al. (2023) The benefits of estetrol addition to drospirenone for contraception. *AJOG Glob Rep* 3(4):100266
- Fruzzetti F et al. (2021) Estetrol: A new choice for contraception. *J Clin Med* 10(23):5625
- Genazzani AR et al. (2007) Drospirenone and its antialdosterone properties. *Climacteric* 10(Suppl 1):11–8
- Gérard C u. Foidart JM (2023) Estetrol: From preclinical to clinical pharmacology and advances in the understanding of the molecular mechanism of action. *Drugs R D* 23:77–92
- Goeckenjan M (2023) Hormonmüdigkeit – Ist das Kupfer-IUP die Alternative? *Gynäkologie* 56:614–22
- Grandi G et al. (2017) Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? *Eur J Contracept Reprod Health Care* 22(4):245–54
- Grandi G et al. (2020) Estetrol (E4): the new estrogenic component of combined oral contraceptives. *Expert Rev Clin Pharmacol* 13(4):327–30
- Hagen AA et al. (1965) Metabolism of 17-betaestradiol-4-14-C in early infancy. *Acta Endocrinol* 49:207–20
- Hilgers RHP et al. (2012) Vasorelaxing effects of estetrol in rat arteries. *J Endocrinol* 215:97–106
- Jensen JT et al. (2022) Pooled efficacy results of estetrol/drospirenone combined oral contraception phase 3 trials. *Contraception* 116:37–43
- Kaunitz AM et al. (2022) Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol/drospirenone on bleeding patterns in healthy women. *Contraception* 116:29–36
- Klippling C et al. (2021) Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. *Contraception* 103(4):213–21
- Kluft C et al. (2017) Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol. *Contraception* 95:140–7
- Krattenmacher R (2000) Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. *Contraception* 62:29–38
- Levine MG et al. (1984) Uterine vascular effects of estetrol in nonpregnant ewes. *Am J Obstet Gynecol* 148:735–8
- Mawet M et al. (2015) Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. *Eur J Contracept Reprod Health Care* 20:463–75
- Morimont L et al. (2021) Combined oral contraceptives and venous thromboembolism: Review and perspective to mitigate the risk. *Front Endocrinol* 12:769187
- Muhn P et al. (1995) Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. *Ann N Y Acad Sci* 761:311–35
- Palacios S et al. (2019) Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. *Acta Obstet Gynecol Scand* 98:1549–57
- Pluchino N et al. (2014) Effect of estetrol administration on brain and serum allopregnanolone in intact and ovariectomized rats. *J Steroid Biochem Mol Biol* 143:285–290.
- Pluchino N et al. (2015) Effect of estetrol on beta-endorphin level in female rats. *Steroids* 95:104–10
- Regidor PA et al. (2023) Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. *Womens Health* 19:17455057221147388
- Regidor PA u. Colli E (2022) Drospirenone 4mg in a 24/4 regimen maintains inhibition of ovulation even after a 24-h delay pill intake - Pharmacological aspects and comparison to other progestin-only pills. *Eur Rev Med Pharmacol Sci* 26(6):1994–9
- Römer T (2023) Übersicht zu hormonellen Kontrazeptiva. *Gynäkologie* 56:587–96
- Teal S, Edelman A (2021) Contraception selection, effectiveness, and adverse effects. *JAMA* 326(24):2507–18
- Tskitishvili E et al. (2014) Estetrol attenuates neonatal hypoxic-ischemic brain injury. *Exp Neurol* 261:298–307
- Tskitishvili E et al. (2017) Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study. *J Endocrinol* 232(1):85–95
- Visser M et al. (2008) First human exposure to exogenous single-dose oral estetrol in early postmenopausal women. *Climacteric* 11:31–40